We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05403476
Recruitment Status : Recruiting
First Posted : June 3, 2022
Last Update Posted : September 7, 2022
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Brief Summary:
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment).

Condition or disease Intervention/treatment Phase
Male Idiopathic Infertility Drug: FE 999049 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of FE 999049 for Treatment of Men With Idiopathic Infertility
Actual Study Start Date : August 16, 2022
Estimated Primary Completion Date : December 24, 2024
Estimated Study Completion Date : December 24, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: FE 999049 (Follitropin Delta) Drug: FE 999049
FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Other Names:
  • REKOVELLE
  • Follitropin Delta

Placebo Comparator: Placebo Drug: Placebo
Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.




Primary Outcome Measures :
  1. Spontaneous pregnancy observed in female partner within 9 months after randomization of male subject, where spontaneous pregnancy is defined as vital pregnancy [ Time Frame: Up to 9 months after randomization ]
    Vital pregnancy is documentation of at least one intrauterine gestational sac with fetal heartbeat by ultrasound.


Secondary Outcome Measures :
  1. Positive Beta-Human Chorionic Gonadotropins (βhCG) (positive urine βhCG test) observed in female partner [ Time Frame: Up to 9 months (End-of-Trial) ]
  2. Time from randomization to spontaneous pregnancy observed in female partner in calendar time and number of menstrual cycles [ Time Frame: Up to 9 months (End-of-Trial) ]
  3. Changes in semen volume from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  4. Changes in sperm concentration from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  5. Changes in total sperm count from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  6. Changes in total motile sperm count from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  7. Changes in sperm morphology from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  8. Changes in semen DNA fragmentation from pre-randomization to 3, 6, and 9 months after randomization [ Time Frame: From pre-randomization to 3, 6 and 9 months after randomization ]
  9. Treatment responders defined by either spontaneous pregnancy observed in female partner, or increase of total sperm count or total motile sperm count to 50% over average baseline at 6 and/or 9 months [ Time Frame: Baseline to 6 and 9 months ]
  10. Changes in follicle stimulating hormone (FSH) from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
  11. Changes in luteinising hormone (LH) from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
  12. Changes in inhibin B from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
  13. Changes in testosterone from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
  14. Changes in estradiol from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
  15. Changes in free testosterone concentration from randomization to 3 and 6 months after randomization [ Time Frame: From randomization to 3 and 6 months after randomization ]
    Blood samples for assessment of sex hormone binding globulin (SHBG) concentrations will be drawn in order to calculate free testosterone concentrations.

  16. Treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity [ Time Frame: From randomization to 21-35 days after End-of-treatment ]
    Blood samples for assessment of anti-FSH antibodies will be drawn.

  17. Immune-related adverse events [ Time Frame: From randomization to End-of-Trial (up to 9 months) ]
    All treatment-emergent adverse events will be analyzed to identify those that potentially are immune related.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of infertility for 12-60 months with current partner at randomization.
  • Men between the ages of 18 and 50 years.
  • Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
  • Total motile sperm count of 5-16 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
  • Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
  • Serum follicle-stimulating hormone (FSH) levels of 1.5-8.0 IU/L (measured at central laboratory) at screening.
  • Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening.
  • Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening.
  • Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomization.
  • Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health.

Current partner fulfilling the criteria below:

  • Pre-menopausal woman between the ages of 18 and 35 years.
  • Regular menstrual cycles of 21-35 days.
  • No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation.
  • Agree not to obtain infertility treatment outside of this trial for 9 months from randomization of male subject.

Exclusion Criteria:

  • Previous FSH treatment not leading to conception.
  • Past or current use of finasteride within 3 months prior to screening.
  • Any history of anatomical disorder of the pituitary gland or testes.
  • Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening.
  • Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility.
  • Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable).
  • Known history of cryptorchidism, testicular torsion, or orchitis.
  • Known abnormal karyotype (including Y-chromosome microdeletion).
  • Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes.
  • Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders).
  • Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05403476


Contacts
Layout table for location contacts
Contact: Global Clinical Compliance +1 833-548-1402 (US/Canada) DK0-Disclosure@ferring.com
Contact: Global Clinical Compliance +1 862-286-5200 (outside US) DK0-Disclosure@ferring.com

Locations
Layout table for location information
United States, Delaware
Ferring Investigational Site Recruiting
Newark, Delaware, United States, 19713
United States, North Carolina
Ferring Investigational Site Recruiting
Raleigh, North Carolina, United States, 27607
United States, Texas
Ferring Investigational Site Recruiting
Bedford, Texas, United States, 76022
Ferring investigational site Recruiting
Webster, Texas, United States, 77598
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Global Clinical Compliance Ferring Pharmaceuticals
Layout table for additonal information
Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05403476    
Other Study ID Numbers: 000400
First Posted: June 3, 2022    Key Record Dates
Last Update Posted: September 7, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs